• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Quiz

Article

Dermatology Times Spot Test: June 14, 2025

Key Takeaways

  • Bimekizumab showed sustained efficacy and inflammation control in psoriatic arthritis and axial spondyloarthritis over three years.
  • Guselkumab is the only IL-23 inhibitor proven to significantly inhibit joint structural damage progression in active psoriatic arthritis.
SHOW MORE

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Dermatology Times Spot Test logo

Dermatology Times presents: Spot Test!

Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.

This week, we’ll focus on recent developments and updates in psoriatic arthritis from the ongoing European Alliance of Associations for Rheumatology 2025 Congress.

Do you have a set of quiz questions to share? Contact editor Emma Andrus at eandrus@mjhlifesciences.com to contribute!

Which dual cytokine pathway does bimekizumab (Bimzelx) target in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA)?


In the BE OPTIMAL, BE COMPLETE, and BE VITAL trials, what percentage of patients with active PsA achieved elimination of swollen joints (SJC=0) at 3 years with bimekizumab, regardless of prior treatment exposure?


Which biologic is currently the only IL-23 inhibitor shown in phase 3 trials to significantly inhibit progression of joint structural damage in PsA?


References

  1. BIMZELX (bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis. News release. UCB. Published June 11, 2024. Accessed June 12, 2025. https://www.ucb.com/newsroom/press-releases/article/bimzelxrvbimekizumab-three-year-data-at-eular-2025-showed-lasting-efficacy-and-control-of-inflammation-in-psoriatic-arthritis-and-axial-spondyloarthritis
  2. New data show TREMFYA (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis. News release. Johnson & Johnson. June 11, 2025. Accessed June 12, 2025. https://www.jnj.com/media-center/press-releases/new-data-show-tremfya-guselkumab-is-the-only-il-23-inhibitor-proven-to-significantly-inhibit-progression-of-joint-structural-damage-in-active-psoriatic-arthritis

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.